Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials (Pending:PBLS)
· seekingalpha.com
Parabilis Medicines, Inc.’s IPO spotlights Helicon peptide cancer drugs like zolucatetide, plus Regeneron’s $125M backing & $329M runway. Click for a look at PBLS.
Donovan Jones is an IPO research specialist with 15 years of experience analyzing investment opportunities for U.S. IPOs.He also leads the investing group IPO E...